10% Off
Iprex20 ml
Square Pharmaceuticals PLC.
৳117.79
Add to cart
Generic medicine
Ipratropium Bromide: Brands, Price & Uses in Bangladesh
Ipratropium Bromide is a short-acting anticholinergic (antimuscarinic) bronchodilator used in respiratory disease.
About Ipratropium Bromide
Indications of Ipratropium Bromide
Ipratropium Bromide is a short-acting anticholinergic (antimuscarinic) bronchodilator used in respiratory disease. Its uses are classified below by strength of evidence:
- Established/FDA-approved use — Chronic Obstructive Pulmonary Disease (COPD): Maintenance treatment of bronchospasm associated with chronic bronchitis and emphysema, delivered by metered-dose inhaler or nebulizer solution.
- Established/FDA-approved use — Rhinorrhea: Nasal spray formulations of Ipratropium Bromide (0.03% and 0.06%) are indicated for symptomatic relief of rhinorrhea associated with allergic and non-allergic perennial rhinitis, and with the common cold, respectively.
- Guideline-supported adjunct use — Acute asthma exacerbation: Nebulized Ipratropium Bromide is recommended by asthma management guidelines as an add-on to inhaled short-acting beta-agonists (SABA) in the emergency treatment of moderate-to-severe acute asthma attacks; it is used in combination with a SABA, not as monotherapy, and is not intended as a stand-alone rescue medication.
- Combination therapy: Ipratropium Bromide is frequently formulated together with albuterol (salbutamol) for combined bronchodilation in COPD and acute bronchospasm, taking advantage of the two drugs' complementary mechanisms.
Ipratropium Bromide is not indicated as the sole agent for rapid relief of acute bronchospasm, since its onset of action is slower than that of short-acting beta-agonists.
Dosage & Administration of Ipratropium Bromide
Dosage by Indication
| Indication | Population | Typical Dose |
|---|---|---|
| COPD maintenance (metered-dose inhaler) | Adults | 2 inhalations (approx. 36 mcg) four times daily; additional inhalations may be needed but total should not exceed 12 inhalations in 24 hours. |
| COPD maintenance (nebulizer solution) | Adults | 500 mcg (one unit-dose vial) by nebulizer 3–4 times daily, doses spaced 6–8 hours apart. |
| Acute asthma exacerbation (adjunct to SABA, nebulized) | Adults | 500 mcg nebulized, combined with a short-acting beta-agonist, repeated at intervals as directed by the treating physician (e.g., every 20 minutes for up to 3 doses in the emergency setting, then as needed). |
| Acute asthma exacerbation (adjunct to SABA, nebulized) | Children (guideline-directed, off-label for Ipratropium Bromide alone in this setting) | 250 mcg (younger children) to 500 mcg (older children/adolescents) nebulized with a SABA, under direct medical supervision; safety and efficacy of routine outpatient use not established. |
| Rhinorrhea (nasal spray 0.03%) | Adults and children ≥6 years | 2 sprays per nostril 2–3 times daily. |
| Rhinorrhea associated with common cold (nasal spray 0.06%) | Adults and children ≥5 years | 2 sprays per nostril 3–4 times daily, for up to 4 days. |
No specific dose adjustment is well established for renal or hepatic impairment given the drug's minimal systemic absorption; use with the usual clinical caution in patients with significant organ impairment.
Administration
For inhaler use, shake the canister and prime before first use or after a period of non-use, as directed in the product leaflet; avoid spraying into the eyes. For nebulizer solution, the contents of the unit-dose vial are placed in the nebulizer chamber (undiluted or diluted as instructed) and inhaled via mouthpiece or well-fitting mask, again taking care to avoid contact with the eyes. Nasal spray should be primed before first use, and the head should be kept upright with sniffing avoided to reduce swallowing of the drug down the throat. Ipratropium Bromide should be used exactly as prescribed; do not exceed the recommended frequency or number of inhalations/sprays without medical advice.
Side Effects of Ipratropium Bromide
The most commonly reported adverse effects of Ipratropium Bromide are related to its local anticholinergic action:
- Very common/common: dry mouth, headache, cough, and throat irritation.
- Common: nausea, dizziness, dyspepsia (indigestion), and blurred vision (especially with accidental eye contact).
- Uncommon: palpitations, tachycardia, urinary retention or difficulty voiding (particularly in patients with pre-existing bladder outlet obstruction), and constipation.
- Rare but serious: paradoxical bronchospasm (a sudden worsening of wheeze/breathlessness immediately after use — treatment should be discontinued and alternative therapy sought if this occurs), acute angle-closure glaucoma or worsening of narrow-angle glaucoma from ocular exposure, and immediate hypersensitivity reactions such as angioedema, urticaria, or anaphylaxis (see Contraindications).
Contraindications of Ipratropium Bromide
Ipratropium Bromide is contraindicated in patients with known hypersensitivity to Ipratropium Bromide, atropine, or any of its derivatives, or to any other component of the formulation. Reported hypersensitivity reactions include urticaria, angioedema (including of the tongue, lips, and face), laryngospasm, and anaphylaxis.
Frequently Asked Questions about Ipratropium Bromide
What is Ipratropium Bromide used for?
Ipratropium Bromide is an inhaled anticholinergic bronchodilator used mainly for long-term maintenance treatment of bronchospasm in chronic obstructive pulmonary disease (COPD), and, as an adjunct to short-acting beta-agonist inhalers, in the emergency treatment of acute asthma exacerbations. Nasal spray forms of Ipratropium Bromide are also used to relieve a runny nose (rhinorrhea) due to allergic rhinitis or the common cold.
Can Ipratropium Bromide be used to stop a sudden asthma attack on its own?
No. Ipratropium Bromide has a slower onset of action than short-acting beta-agonist rescue inhalers (such as salbutamol) and is not intended as a stand-alone rescue medication for sudden bronchospasm. In an acute asthma attack, Ipratropium Bromide is used together with, not instead of, a fast-acting beta-agonist, under medical guidance.
Who should not use Ipratropium Bromide?
Ipratropium Bromide should not be used by anyone with a known allergy (hypersensitivity) to Ipratropium Bromide itself, to atropine, or to related anticholinergic derivatives, as this can cause reactions such as swelling of the face and throat, hives, or a severe allergic reaction. Always tell your doctor about any known drug allergies before starting Ipratropium Bromide.
What are the common side effects of Ipratropium Bromide?
The most common side effects of Ipratropium Bromide are dry mouth, cough, headache, and a bitter or unusual taste. Some people experience nausea, dizziness, or blurred vision, especially if the spray or mist accidentally gets into the eyes. If you notice sudden worsening of wheezing or breathing difficulty right after using Ipratropium Bromide (paradoxical bronchospasm), stop use and contact your doctor immediately.
Is Ipratropium Bromide safe to use during pregnancy or breastfeeding?
There is limited human data on Ipratropium Bromide in pregnancy and breastfeeding. Because very little of the drug is absorbed into the bloodstream after inhaled or nasal use, exposure to a fetus or breastfed infant is expected to be low, but Ipratropium Bromide should be used during pregnancy or breastfeeding only if your physician determines that the benefit outweighs any potential risk. Always consult your doctor before using Ipratropium Bromide if you are pregnant, planning pregnancy, or breastfeeding.
Can Ipratropium Bromide be used in children?
Yes, but the approved age depends on the product: Ipratropium Bromide nasal spray (0.03%) is approved for children 6 years and older, and the 0.06% strength for children 5 years and older for cold-related runny nose. Nebulized Ipratropium Bromide is often used as an add-on treatment for acute asthma attacks in children under close medical supervision, but its routine safety and effectiveness for regular use at home has not been formally established in young children, so pediatric use should always be directed by a doctor.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.